News

Bladder Cancer Research Centre launches in Birmingham

A new research centre which aims to overcome barriers for a common, but often overlooked cancer has opened at BHP founder-member the University of Birmingham. Bladder cancer is relatively common cancer in the UK, with over 10,000 patients diagnosed each year in the UK and approximately 40-50,000 patients living with the disease at any one … Continue reading “Bladder Cancer Research Centre launches in Birmingham”

Why drug repurposing is the route of choice when speed is of the essence

The COVID-19 pandemic has rapidly changed the delivery of healthcare.¬† It has stimulated rapid innovation in medical diagnostics and equipment, and the manufacturing sector has responded with flexible, demand-led manufacturing of ventilators and PPE.¬† But the first round of clinical trials for COVID featured drugs that were already on the market, and aimed to repurpose … Continue reading “Why drug repurposing is the route of choice when speed is of the essence”

Immunotherapy hope for rare abdominal cancer

A new study from BHP founder-member the University of Birmingham has found that 50% of patients with a rare type of abdominal lining cancer may be suitable for immunotherapy treatment. Unfortunately for around 1% of bowel cancer patients, their cancer spreads to the lining of their abdomen (peritoneal cavity) – known as colorectal peritoneal metastasis … Continue reading “Immunotherapy hope for rare abdominal cancer”

Cellular immunity to COVID-19 found at six months in non-hospitalised individuals

Cellular (T cell) immunity against SARS-CoV-2 is likely to be present within most adults six months after primary infection, a new pre-print on bioRxiv suggests. The research from Public Health England and the UK Coronavirus Immunology Consortium (UK-CIC) demonstrates robust T cell responses to SARS-CoV-2 virus peptides at this timepoint in all participants following asymptomatic … Continue reading “Cellular immunity to COVID-19 found at six months in non-hospitalised individuals”

New mouth spray could benefit patients with painful genetic skin condition

A new spray for treating severely painful blisters, mouth ulceration and oral scarring in patients with a rare genetic skin condition is being developed by researchers at BHP founder-member the University of Birmingham. The spray is designed for patients with¬†Epidermolysis Bullosa (EB), a condition that causes the skin to blister and tear at the slightest … Continue reading “New mouth spray could benefit patients with painful genetic skin condition”